Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
This research study is looking at how best to help people with Alzheimer's disease. In France, there's been some debate about whether a drug called donepezil is truly effective, and their health system no longer pays for it. Instead, they often suggest non-drug approaches, like activities to keep your memory and thinking sharp. This study aims to compare these two main approaches over six months. Some participants will receive donepezil alongside general care, while others will focus solely on non-drug support, such as speech therapy or special home visits for memory exercises. The goal is to understand which method helps people with Alzheimer's symptoms the most.
De un vistazo
¿De qué trata este estudio?
This study is designed to help us understand the best ways to support people living with Alzheimer's disease. There's a discussion in the medical community, particularly in France, about how effective a specific drug called donepezil really is. Because of these questions, the French healthcare system has stopped covering the cost of donepezil. Instead, their health experts often recommend non-drug treatments, which focus on activities and support to keep someone's mind active and help with daily life.
The main goal of this research is to directly compare these two different ways of helping. We want to see if donepezil, combined with standard support, works better than just using non-drug approaches on their own for improving the symptoms of Alzheimer's disease. The study will look at how participants are doing after six months of whichever treatment they receive.
In this study, people will be divided into two groups. One group will receive the usual care, which involves non-drug approaches. This kind of care focuses on the person and their surroundings, using things like memory exercises, emotional support, and practical help. It is often provided by specialists in memory clinics, such as speech therapists or special teams who visit homes for memory training. The second group will receive the same usual care, but they will also take donepezil tablets every day. Researchers will then compare how both groups manage their symptoms over the six-month period.
Puntos clave
- Compares donepezil drug vs. non-drug memory support.
- Aims to see which is better for Alzheimer's symptoms.
- Study lasts for six months.
- Open to people 50+ with early-onset Alzheimer's.
- Non-drug care includes memory exercises and specialist support.
- Important for understanding future Alzheimer's care.
¿Quién puede ser elegible?
To join this study, people need to have a confirmed diagnosis of Alzheimer's disease based on specific medical guidelines, and they must be at least 50 years old. They also need to be able to make their own decisions about taking part in the study, and have a close family member or carer who can help make sure they take their medication correctly if needed. Participants also need to speak French.
There are several reasons why someone might not be able to join. This includes having another cause for memory problems, having taken Alzheimer's medication before, or being allergic to donepezil. People with certain heart conditions, a history of fits, severe liver problems, or specific breathing issues like severe asthma, may also not be able to take part. Researchers also need to check if you are taking other medications that might react badly with donepezil or affect the study results.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Do you have a diagnosis of Alzheimer's disease?
- Are you 50 years old or older?
- Can you make your own decisions about your healthcare?
- Is a family member or carer available to help with treatment if needed?
- Are you a native French speaker?
- Have you *not* taken other Alzheimer's drugs before?
¿En qué consiste la participación?
If you decide to take part in this study, you will be in one of two groups. One group will receive standard care, which involves non-drug treatments like memory exercises and support. The other group will receive this same standard care, but they will also take a donepezil tablet once a day. You'll start with a lower dose (5mg) for the first month, then increase to a standard dose (10mg) for the remaining five months.
This study will last for six months. During this time, you will have regular check-ups and assessments with the study team. These visits will help the researchers understand how you are responding to the assigned treatment and monitor your health. All care will be based on recommendations from French health authorities. The exact number of visits and tests will be explained in detail by the study team.
Riesgos y beneficios potenciales
Ubicaciones (1)
- Cognitive Neurology CenterCódigo postal verificadoParís, Francia· Reclutamiento
Preguntas comunes
What is Donepezil?
Donepezil is a medication that is sometimes used to help with the symptoms of Alzheimer's disease by affecting brain chemicals.
What are 'non-drug treatments'?
These are therapies like memory exercises, special activities, and support designed to keep your mind stimulated and help with daily living, without using medication.
¿Cuánto tiempo durará el estudio?
The treatment period for this study is six months, during which your progress will be monitored.
Will I know which treatment I'm receiving?
Yes, this is an 'open-label' study, meaning both you and the researchers will know whether you are receiving donepezil or non-drug care.
¿Quién está financiando esta investigación?
The information provided doesn't state the funding source, but this is a good question to ask the study team.
Cómo obtener más información
DUMURGIER Julien, MD, PhD
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.